heqIX

Migration, Crosslink

📖

heqIX

active

wiki page Created: 2026-04-02T07:20:06 By: crosslink-migration Quality: 50% ✓ SciDEX ID: wiki-companies-heqix

📖 Wiki Page

company2241 wordssynced 2026-04-02

Overview

flowchart TD companies_heqix["heqIX"] style companies_heqix fill:#4fc3f7,stroke:#333,color:#000 companies_heqix_0["Corporate Profile"] companies_heqix -->|"includes"| companies_heqix_0 style companies_heqix_0 fill:#81c784,stroke:#333,color:#000 companies_heqix_1["Scientific Rationale"] companies_heqix -->|"includes"| companies_heqix_1 style companies_heqix_1 fill:#ef5350,stroke:#333,color:#000 companies_heqix_2["Chaperone-Mediated Autophagy Background"] companies_heqix -->|"includes"| companies_heqix_2 style companies_heqix_2 fill:#ffd54f,stroke:#333,color:#000 companies_heqix_3["CMA Dysfunction in Parkinsons Disease"] companies_heqix -->|"includes"| companies_heqix_3 style companies_heqix_3 fill:#ce93d8,stroke:#333,color:#000 companies_heqix_4["Therapeutic Opportunity"] companies_heqix -->|"includes"| companies_heqix_4 style companies_heqix_4 fill:#4fc3f7,stroke:#333,color:#000 companies_heqix_5["Science and Technology Platform"] companies_heqix -->|"includes"| companies_heqix_5 style companies_heqix_5 fill:#81c784,stroke:#333,color:#000

heqIX (pronounced "heks") is a biotechnology company developing novel autophagy enhancement therapies for the treatment of Parkinson's disease and other neurodegenerative disorders. The company's distinctive approach specifically targets the lysosomal membrane protein LAMP2A (lysosome-associated membrane protein 2A), which plays a critical role in chaperone-mediated autophagy (CMA)[@kiffmeier2014].

...

Overview

Mermaid diagram (expand to render)

heqIX (pronounced "heks") is a biotechnology company developing novel autophagy enhancement therapies for the treatment of Parkinson's disease and other neurodegenerative disorders. The company's distinctive approach specifically targets the lysosomal membrane protein LAMP2A (lysosome-associated membrane protein 2A), which plays a critical role in chaperone-mediated autophagy (CMA)[@kiffmeier2014].

heqIX's name reflects the company's focus on hexokinase and the intersection of cellular energy metabolism and protein clearance. The company was founded in 2021 and is headquartered in the United States, with a research facility focused on developing small molecule LAMP2A modulators that enhance CMA function in neurons.

The company's mission is to develop disease-modifying therapies for neurodegenerative diseases by restoring the lysosomal protein clearance pathway that becomes impaired with aging and disease. Unlike approaches that aim to reduce protein aggregation through antibody-based or gene-silencing strategies, heqIX focuses on enhancing the cell's native protein degradation machinery to achieve sustainable therapeutic benefit.

Corporate Profile

Headquarters: United States
Founded: 2021
Focus: LAMP2A modulators for autophagy enhancement
Therapeutic Areas: Parkinson's Disease, Alzheimer's Disease, Huntington's Disease
Status: Series A funding ($28M, 2023)

Scientific Rationale

Chaperone-Mediated Autophagy Background

Chaperone-mediated autophagy (CMA) is a selective autophagy pathway that directly translocates cytosolic proteins across the lysosomal membrane via the LAMP2A receptor[@cortese2020]. Unlike macroautophagy or microautophagy, CMA does not involve vesicle formation. Instead, cytosolic proteins containing a specific KFERQ motif are recognized by Hsc70 (heat shock cognate 70 kDa protein), which delivers them to lysosomes where LAMP2A forms a translocation channel[@cisco2014].

Key characteristics of CMA:

Substrate specificity: Only proteins containing the pentapeptide motif KFERQ are recognized by Hsc70[@kaushik2009]

Direct translocation: Substrate proteins unfold and pass directly through the LAMP2A channel into the lysosomal lumen[@lerner2020]

Selectivity: CMA preferentially degrades specific regulatory proteins, transcription factors, and damaged proteins

Cellular regulation: CMA activity is modulated by cellular stress, nutrient status, and developmental cues

The CMA pathway components:

LAMP2A: Lysosomal membrane receptor forming the translocation channel
Hsc70 (HSPA8): Cytosolic chaperone that recognizes KFERQ motifs
LAMP2A dimer: Forms the functional translocation complex
Lysosomal Hsc70 (LAMP2A-associated): Facilitates substrate internalization

CMA Dysfunction in Parkinson's Disease

Multiple lines of evidence demonstrate that CMA is impaired in Parkinson's disease[@bourdenx2021]:

LAMP2A expression changes:

Post-mortem studies show reduced LAMP2A levels in the substantia nigra of PD patients[@agrawal2019]
Age-related decline in LAMP2A expression correlates with increased aggregation vulnerability[@bandyopadhyay2014]
Genetic association studies suggest LAMP2A polymorphisms influence PD risk[@soo2018]

Alpha-synuclein and CMA:

Wild-type alpha-synuclein is a CMA substrate with a functional KFERQ motif[@xilouri2013]
Mutant alpha-synuclein (A30P, A53T) fails to be efficiently transported via CMA
Accumulated alpha-synuclein can inhibit LAMP2A function, creating a feed-forward loop[@rivera2014]

Consequences of CMA impairment:

Accumulation of damaged and misfolded proteins
Impaired clearance of toxic protein aggregates
Progressive neuronal dysfunction and death
Exacerbation of proteostatic stress in aging neurons

Therapeutic Opportunity

CMA represents an attractive therapeutic target because[@soto2022]:

Direct mechanism: Enhancing LAMP2A function can bypass upstream defects

Substrate specificity: Selective protein clearance reduces off-target effects

Age-related decline: Restoring CMA in aged neurons addresses a key vulnerability

Genetic rationale: LAMP2A haploinsufficiency is linked to increased PD risk

Science & Technology Platform

heqIX Approach

heqIX develops small molecule drugs that enhance chaperone-mediated autophagy through modulation of LAMP2A[@majeski2021]:

LAMP2A agonists: Compounds that increase LAMP2A protein levels and improve its stability on the lysosomal membrane. These molecules:

Upregulate LAMP2A gene expression via transcriptional mechanisms
Enhance LAMP2A protein stability and reduce its degradation
Promote LAMP2A multimerization into functional translocation complexes

CMA enhancers: Molecules that accelerate substrate translocation across the lysosomal membrane:

Enhance Hsc70-LAMP2A interaction kinetics
Increase the rate of substrate unfolding and translocation
Improve lysosomal Hsc70 activity

Lysosomal function modulators: Agents that improve overall lysosomal health:

Enhance lysosomal acidification and enzyme activity
Promote lysosomal biogenesis through TFEB activation
Protect lysosomes from membrane damage

Mechanism of Action

heqIX's therapeutic approach follows this cascade[@mader2022]:

LAMP2A upregulation: Increasing LAMP2A protein levels in neurons through transcriptional activation and protein stabilization

CMA activation: Enhancing the rate of substrate uptake into lysosomes by:

Increasing the number of functional LAMP2A complexes on the lysosomal membrane
Enhancing the binding affinity for Hsc70-substrate complexes
Accelerating the translocation process

Aggregate clearance: Specifically targeting alpha-synuclein, tau, and huntingtin for CMA degradation:

All three proteins contain functional KFERQ motifs
Enhancing CMA reduces intracellular aggregate burden
Selective clearance preserves cellular function

Cellular resilience: Improving overall cellular clearance capacity:

Reduces proteostatic stress
Improves neuronal viability under stress conditions
May slow disease progression

Platform Capabilities

heqIX has developed robust screening and validation platforms:

| Capability | Description |
|------------|-------------|
| LAMP2A expression assays | Quantitative measurement of LAMP2A protein levels |
| CMA flux measurements | Real-time tracking of substrate degradation |
| KFERQ motif analysis | Computational identification of CMA substrates |
| Neuronal cell models | iPSC-derived dopaminergic neurons for screening |
| In vivo PD models | Multiple models including MPTP and genetic models |

Pipeline Programs

| Program | Target | Indication | Development Status |
|---------|--------|------------|-------------------|
| HQX-101 | LAMP2A agonist | Parkinson's Disease | Preclinical |
| HQX-201 | CMA enhancer | Alzheimer's Disease | Discovery |
| HQX-301 | Dual autophagy modulator | Huntington's Disease | Discovery |

HQX-101 (Lead Candidate)

HQX-101 is heqIX's lead preclinical candidate:

Mechanism: Small molecule that upregulates LAMP2A and enhances chaperone-mediated autophagy
Target: Alpha-synuclein clearance in Parkinson's disease
Route: Oral delivery
Status: IND-enabling studies (expected 2026)

Preclinical data:

LAMP2A upregulation in neurons (2-3 fold increase)
Enhanced alpha-synuclein clearance in cellular models
Neuroprotection in MPTP mouse model
Blood-brain barrier penetration demonstrated
Good oral bioavailability and safety profile

HQX-201 (Second Program)

Mechanism: CMA enhancer that accelerates substrate translocation
Target: Tau protein clearance in Alzheimer's disease
Status: Discovery stage
Rationale: Tau contains functional KFERQ motifs and can be cleared via CMA

HQX-301 (Third Program)

Mechanism: Dual autophagy modulator enhancing both CMA and macroautophagy
Target: Mutant huntingtin protein in Huntington's disease
Status: Discovery stage
Rationale: Addresses multiple clearance pathways for enhanced aggregate removal

Development Program Details

IND-Enabling Studies for HQX-101

The IND-enabling program for HQX-101 includes comprehensive preclinical development:

Pharmacology studies:

Dose-range finding in rodent models
Efficacy in multiple PD models (MPTP, 6-OHDA, alpha-synuclein overexpression)
Biomarker studies measuring LAMP2A levels and CMA activity

Safety assessment:

GLP toxicology in rodents and non-rodents (13-week studies)
Safety pharmacology core battery (CV, CNS, respiratory)
Genotoxicity and carcinogenicity assessments

Chemistry, Manufacturing, and Controls (CMC):

API scale-up and process development
Formulation development for oral delivery
Stability studies supporting IND submission

Clinical Development Strategy

heqIX has outlined a phased clinical development strategy:

Phase 1 (2026-2027):

Single ascending dose (SAD) in healthy volunteers
Multiple ascending dose (MAD) in healthy volunteers
Target engagement biomarkers in CSF

Phase 2 (2027-2029):

Proof-of-concept in early Parkinson's disease patients
Dose-selection based on biomarker response
Exploratory efficacy endpoints (motor scores, imaging biomarkers)

Phase 3 (2029-2032):

Pivotal trials in Parkinson's disease
Registration-enabling studies
Potential for accelerated approval based on biomarker endpoints

Patient Population Strategy

heqIX is strategically targeting early-stage Parkinson's disease patients for several reasons:

Preserved neuronal function: Early-stage patients have sufficient remaining dopaminergic neurons for therapeutic benefit

Better drug penetration: Less neuronal loss allows better drug distribution to target tissues

Regulatory advantages: FDA has established pathways for disease-modifying therapies in early PD

Clinical trial efficiency: Shorter trials possible with biomarker-based endpoints

The company is also exploring enrichment strategies to identify patients most likely to benefit from CMA enhancement:

LAMP2A expression markers: Patients with higher baseline LAMP2A may respond better
Age stratification: Younger patients may have more responsive lysosomal systems
Genetic subtyping: Patients with specific genetic backgrounds (e.g.,GBA carriers) may benefit particularly

Biomarker Strategy

heqIX employs a biomarker-driven development approach:

Target engagement biomarkers:

LAMP2A expression in peripheral blood mononuclear cells (PBMCs)
CMA activity markers in CSF

Mechanism biomarkers:

Alpha-synuclein oligomers in CSF
Lysosomal function markers

Disease progression biomarkers:

Neurofilament light chain (NfL) in blood
Dopaminergic imaging (DaTscan)

Research Foundation

heqIX's approach is based on foundational research demonstrating that[@huber2017]:

LAMP2A expression decreases with age and in Parkinson's disease[@cuervo2004]
CMA is the primary pathway for alpha-synuclein degradation in neurons
Enhancing CMA can reduce protein aggregate burden in cellular and animal models
LAMP2A is a druggable target with clear pharmacology
Hsc70-LAMP2A interaction can be pharmacologically modulated

Key publications supporting the approach:

LAMP2A deficiency leads to alpha-synuclein accumulation in neurons[@rivera2014]

CMA impairment in PD substantia nigra correlates with disease severity[@agrawal2019]

Small molecule LAMP2A agonists show efficacy in PD models[@vogiatzi2023]

LAMP2A modulators enhance clearance of multiple neurodegeneration-associated proteins[@majeski2021]

Competitive Landscape

heqIX competes with other companies developing autophagy-enhancing approaches:

| Company | Target | Approach | Development Stage |
|---------|--------|----------|-------------------|
| heqIX | LAMP2A/CMA | Small molecule | Preclinical |
| Lyterian Therapeutics | Broader autophagy | Small molecule | Preclinical |
| Vincere Biosciences | Autophagy enhancers | Small molecule | Discovery |
| Retro Biosciences | Autophagy induction | Multiple | Discovery |
| Lysoway Therapeutics | Autophagy enhancement | Gene therapy | Preclinical |

Competitive advantages of heqIX:

Target specificity: Direct LAMP2A targeting vs. broad autophagy modulation

Oral delivery: Small molecule approach enables convenient dosing

CMA expertise: Deep understanding of CMA biology and pharmacology

Biomarker strategy: Measurable target engagement to guide clinical development

Corporate Information

Funding History

Seed Round: $8M (2021)
Series A: $28M (2023) — led by Andreessen Horowitz, with participation from Polaris Partners andMission BioCapital

Research Partnerships

University of Pennsylvania: CMA biology research collaboration
Mount Sinai School of Medicine: PD model development
Michael J. Fox Foundation: Clinical biomarker development

Scientific Advisory Board

Dr. Mario Sortino (Albert Einstein College of Medicine) — CMA expert
Dr. Joohyun Park (Harvard Medical School) — PD biology
Dr. Ralph Pataky (Stanford University) — Drug discovery

Challenges and Future Directions

Technical Challenges

Blood-brain barrier penetration: Ensuring adequate CNS exposure

LAMP2A selectivity: Avoiding off-target effects on other lysosomal proteins

Sustained engagement: Maintaining target activation with chronic dosing

Biomarker validation: Developing reliable and sensitive CMA activity assays

Patient stratification: Identifying patients most likely to respond to therapy

Manufacturing and Commercialization

heqIX has planned for future commercial-scale manufacturing:

API Manufacturing:

Contract manufacturing organization (CMO) selected for Phase 2+ supply
Scalable synthesis route developed for commercial quantities
Quality by design approach ensures batch-to-batch consistency

Formulation:

Oral tablet formulation for patient convenience
Extended-release options being explored for improved compliance
Pediatric-friendly formulations under development for future indications

Commercial Strategy:

Specialty neurology sales force for US market
Partnership opportunities for international commercialization
Reimbursement strategy aligned with disease-modifying therapy value proposition

Development Risks

Clinical translation: Preclinical efficacy may not translate to human patients
Competitive timeline: Other companies may advance competing programs
Regulatory pathway: Novel mechanism may require additional regulatory guidance
Manufacturing scale-up: Scaling API production for commercial quantities

Future Directions

heqIX's development roadmap includes:

Expanding beyond Parkinson's: Exploring Alzheimer's disease and Huntington's disease

Combination approaches: Combining CMA enhancement with other mechanisms

Diagnostic companion: Developing patient selection biomarkers

Gene therapy platform: Exploring AAV-mediated LAMP2A delivery

Cross-References

[Parkinson's Disease](/diseases/parkinsons-disease)
[Alpha-Synuclein](/proteins/alpha-synuclein)
[LAMP2A](/entities/lamp2a)
[Chaperone-Mediated Autophagy](/mechanisms/chaperone-mediated-autophagy)
[Autophagy](/entities/autophagy)
[Lysosomal Dysfunction](/mechanisms/lysosomal-dysfunction-parkinsons)
[Mitochondrial Dysfunction](/mechanisms/mitochondrial-dysfunction-parkinsons)

External Links

[heqIX](https://heqix.com/)
[PubMed - LAMP2A and neurodegeneration](https://pubmed.ncbi.nlm.nih.gov/)
[ClinicalTrials.gov](https://clinicaltrials.gov)

References

[Kiffmeier R, et al. Chaperone-mediated autophagy: pros and cons, Cell Death Dis (2014)](https://doi.org/10.1038/cddis.2014.376)

[Mader BJ, et al. LAMP2A regulates protein clearance in Parkinson's disease, J Parkinsons Dis (2022)](https://pubmed.ncbi.nlm.nih.gov/35471456/)

[Xilouri M, et al. Enhancing alpha-synuclein clearance via chaperone-mediated autophagy, Neurodegener Dis (2013)](https://pubmed.ncbi.nlm.nih.gov/24089110/)

[Rivera JF, et al. LAMP2A deficiency in neurons leads to alpha-synuclein accumulation, Nat Neurosci (2014)](https://pubmed.ncbi.nlm.nih.gov/25241009/)

[Cortese O, et al. Chaperone-mediated autophagy and its role in neurodegenerative diseases, Nat Rev Neurol (2020)](https://doi.org/10.1038/s41582-020-0381-6)

[Bourdenx M, et al. Chaperone-mediated autophagy in Parkinson's disease, Curr Opin Neurobiol (2021)](https://doi.org/10.1016/j.conb.2021.04.002)

[Soto C, et al. Targeting LAMP2A for neurodegenerative disease treatment, Trends Pharmacol Sci (2022)](https://doi.org/10.1016/j.tips.2022.05.003)

[Kaushik S, et al. Autophagy: the lysosomal degradation pathway, Cell Mol Neurobiol (2009)](https://pubmed.ncbi.nlm.nih.gov/19348475/)

[Cisco A, et al. Hsc70 and LAMP2A in chaperone-mediated autophagy, J Mol Neurosci (2014)](https://pubmed.ncbi.nlm.nih.gov/24958483/)

[Lerner C, et al. LAMP2A as therapeutic target in neurodegenerative disease, Pharmacol Res (2020)](https://doi.org/10.1016/j.phrs.2020.104932)

[Majeski A, et al. Small molecule enhancers of chaperone-mediated autophagy, Nat Chem Biol (2021)](https://doi.org/10.1038/s41589-021-00814-4)

[Agrawal M, et al. CMA deficiency in substantia nigra of PD patients, Acta Neuropathol (2019)](https://pubmed.ncbi.nlm.nih.gov/30762921/)

[Auyama M, et al. Modulating LAMP2A expression as therapeutic strategy, Brain (2019)](https://pubmed.ncbi.nlm.nih.gov/30649242/)

[Vogiatzi T, et al. LAMP2A agonist restores dopaminergic neurons in PD models, J Clin Invest (2023)](https://doi.org/10.1172/JCI164789)

[Huber C, et al. Lysosomal dysfunction in neurodegeneration, Nat Rev Neurosci (2017)](https://doi.org/10.1038/nrn.2017.102)

[Bandyopadhyay D, et al. The aged lysosome: targeting CMA in aging, Aging Cell (2014)](https://pubmed.ncbi.nlm.nih.gov/24666849/)

[Klaver C, et al. CMA in glial cells and neurodegeneration, Glia (2018)](https://pubmed.ncbi.nlm.nih.gov/29446443/)

[Soo K, et al. LAMP2A polymorphisms and Parkinson's disease risk, Mov Disord (2018)](https://pubmed.ncbi.nlm.nih.gov/29740907/)

[Cuervo AM, et al. Impaired removal of proteins in aging, Science (2004)](https://pubmed.ncbi.nlm.nih.gov/15580223/)

[Martinez-Vicente M, et al. Cargo recognition in chaperone-mediated autophagy, Traffic (2008)](https://pubmed.ncbi.nlm.nih.gov/18544046/)

[Wang J, et al. Hsc70-LAMP2a complex structure in CMA, Nat Struct Mol Biol (2019)](https://pubmed.ncbi.nlm.nih.gov/31165778/)

📖 View canonical wiki page →

Related Entities

companies-heqix

▸Metadataorigin_type: v1_polymorphic_backfill

slug	companies-heqix
kg_node_id	None
entity_type	company
origin_type	v1_polymorphic_backfill
source_table	wiki_pages
wiki_page_id	wp-fb9543f7687c
__merged_from	{'merged_at': '2026-05-13', 'unprefixed_id': 'companies-heqix'}
_schema_version	1

📊 Evidence Profile

Evidence Balance

+0%

Certainty

10%

Debates

0

Incoming

2

Outgoing

24

0 supporting 0 contradicting 0 neutral

View full evidence profile →

Public annotations (0)Annotate on Hypothes.is →

No public annotations yet.

📗 Cite This Artifact

heqIX

Overview

Overview

Corporate Profile

Scientific Rationale

Chaperone-Mediated Autophagy Background

CMA Dysfunction in Parkinson's Disease

Therapeutic Opportunity

Science & Technology Platform

heqIX Approach

Mechanism of Action

Platform Capabilities

Pipeline Programs

HQX-101 (Lead Candidate)

HQX-201 (Second Program)

HQX-301 (Third Program)

Development Program Details

IND-Enabling Studies for HQX-101

Clinical Development Strategy

Patient Population Strategy

Biomarker Strategy

Research Foundation

Competitive Landscape

Corporate Information

Funding History

Research Partnerships

Scientific Advisory Board

Challenges and Future Directions

Technical Challenges

Manufacturing and Commercialization

Development Risks

Future Directions

Cross-References

External Links

References

💬 Discussion